论文部分内容阅读
急性白血病是儿童最常见的恶性肿瘤 ,既往治疗效果极差 ,进入 80年代以来 ,预后明显改善 ,目前 70 %的急性淋巴细胞白血病和 40 %的急性髓细胞白血病可长期无病生存。这种治疗的成功 ,既是有效联合化疗方法发展和支持治疗措施改进的结果 ,也与分子生物学的发展促进了白血病的细胞和分子遗传学研究 ,从而能更加准确地鉴定不同预后因素和采用针对性治疗有关。未来白血病的研究重点将集中在发展更加个体化的治疗上 ,以保证长期存活患儿的生存质量及针对耐药白血病探索诱导分化治疗、促凋亡治疗、免疫治疗和基因治疗等新的治疗途径
Acute leukemia is the most common malignant tumor in children. Previous treatment has been very poor. Since the 1980s, the prognosis has been significantly improved. Currently, 70% of acute lymphoblastic leukemia and 40% of acute myeloid leukemia can survive for a long time. The success of this treatment is both an effective adjunct to the development of chemotherapeutic approaches and support for improvements in therapeutic measures, as well as the advances in molecular biology that have contributed to the cellular and molecular genetic studies of leukemias to more accurately identify different prognostic factors and to target Sexual treatment related. The future focus of leukemia research will focus on the development of more individualized treatment in order to ensure the long-term survival of children with quality of life and for the induction of drug resistant leukemia induced differentiation therapy, apoptosis treatment, immunotherapy and gene therapy and other new ways of treatment